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Evaluation of Very High- and Very Low-Dose Intravitreal
Aflibercept in Patients with Neovascular
Age-Related Macular Degeneration
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Peter L. Sonkin,4 Seenu M. Hariprasad,5 Peter K. Kaiser,6 Jason Slakter,7 Julia A. Haller,1
Diana V. Do,1 William Mieler,5 Karen Chu,8 Avner Ingerman,8 Robert Vitti,8
Alyson J. Berliner,8 Jesse Cedarbaum,8 and the CLEAR-IT 1 Investigators
Abstract
Purpose: To determine bioactivity and duration of effect of intravitreal aflibercept injection (also known as
vascular endothelial growth factor Trap-Eye) for neovascular age-related macular degeneration (AMD).
Methods: In this double-masked, phase 1 study, 28 patients with lesions £ 12 disc areas, ‡ 50% active choroidal
neovascularization (CNV), and best corrected visual acuity (BCVA) £ 20/40 were randomized 1:1 to a single
intravitreal injection of aflibercept 0.15 or 4mg. The primary end point was the change from baseline in central
retinal/lesion thickness (CR/LT) at week-8. Secondary outcomes were the change from baseline BCVA, the
change in CNV lesion size and area of leakage, and proportion of patients requiring repeat injection at 8 weeks.
Results: Mean percent decrease in CR/LT for the 4-mg and 0.15-mg groups was, respectively, 34.2 versus 13.3 at
week 4 (P= 0.0065), 23.8 versus 5.9 at week 6 (P= 0.0380), and 25.2% versus 11.3% at week 8 (P= 0.150). The 4-mg
group gained a mean of 4.5 letters in BCVA (6/14 patients gaining ‡ 10 letters) versus 1.1 letters in 0.15-mg
group (1/14 gaining ‡ 10 letters) at week 8. Fewer patients needed retreatment in the 4-mg group at week 8. No
serious adverse event or ocular inflammation was reported in either group.
Conclusions: Intravitreal aflibercept 4mg had a safety profile similar to that of the very low dose 0.15mg, and
was well-tolerated. The 4-mg dose significantly reduced foveal thickening at weeks 4 and 6, significantly im-
proved BCVA at weeks 6, and reduced the need for repeat injection after 8 weeks compared with intravitreal
aflibercept 0.15mg in neovascular AMD patients.
Introduction
V
ascular endothelial growth factor (VEGF) is a
critical stimulus for subretinal and choroidal neo-
vascularization (CNV) in animal models1–4 and its impor-
tance in neovascular age-related macular degeneration
(AMD) has been confirmed.5,6 Ranibizumab, a humanized
monoclonal antibody that binds all isoforms of VEGF-A has
been shown in numerous studies to stabilize and improve
best corrected visual acuity (BCVA) in patients with neo-
vascular AMD,5,6 but frequent intraocular injections are
generally required to maintain those benefits. Development
of VEGF antagonists that are more potent and/or have a
longer duration of action is a high priority.
Aflibercept is a recombinant protein in which the binding
domains of VEGF receptors 1 and 2 have been combined
with the Fc portion of IgG. The receptor portion of the
molecule has a very high affinity for all VEGF-A isoforms
(Kd < 1 pM), Placental Growth Factor (PlGF)-1 and - 2, and
VEGF-B.7 Therefore, aflibercept is distinguished from ranibi-
zumab by its higher binding affinity for all VEGF-A isoforms
and its ability to inhibit other VEGF family members. A
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randomized, multicenter, placebo-controlled clinical trial in-
vestigating the effect of intravenous aflibercept in patients with
neovascular AMD showed elimination of about 60% of excess
retinal thickness after either single or multiple infusions.8 The
maximum tolerated dose of intravenous aflibercept in this
study population was 1.0mg/kg; at 3mg/kg, hypertension,
and proteinuria, which are class effects of systemic anti-VEGF
therapy, were noted. Thus, alternative routes of delivery were
investigated to increase the duration of therapeutic effect and
minimize the potential for adverse events (AEs).
Intravitreal aflibercept injection (also known as VEGF
Trap-Eye) is a formulation utilizing ultrapurified aflibercept
in an iso-osmotic combination of buffers compatible with
intraocular administration. Preclinical and model studies
have suggested that intravitreal aflibercept may maintain a
significant intravitreal VEGF-binding activity for several
weeks after a single injection at doses of 0.5mg and 4mg in
rabbits and humans, respectively (Furfine, et al. Association
for Research in Vision & Ophthalmology. Invest Ophthalmol
Vis Sci, 2006; 47:E-Abstract 1430).9 In a dose-ranging phase 1
trial of 21 patients with advanced neovascular AMD, a single
intravitreal injection of aflibercept at doses from 0.05mg to
4mg was well-tolerated and showed evidence of bioac-
tivity.10 Three of the 6 patients in this study treated with one
intravitreal dose of 2 or 4mg showed improvement in BCVA
‡ 3 lines at the 6-week primary end point.10 The current
study is a prospective randomized trial comparing the visual
and anatomic effects of intravitreal injection of 4mg or
0.15mg of aflibercept in eyes with neovascular AMD, de-
signed to evaluate the bioactivity, safety and tolerability, and
duration of action of the 2 doses of aflibercept.
Methods
The study was a prospective, double-masked, randomized
clinical trial comparing a single intravitreal injection of 0.15
or 4mg of aflibercept in patients with neovascular AMD. The
study was conducted at 5 sites and in compliance with the
Declaration of Helsinki, US Code 21 of Federal Regulations,
and the Harmonized Tripartite Guidelines for Good Clinical
Practice (1996), and was reviewed and approved by all ap-
propriate Institutional Review Boards. All participating pa-
tients provided written informed consent.
Study population
Participants were men or women of any ethnicity, aged 50
years or older, with the diagnosis of neovascular AMD with
subfoveal CNV £ 12 disc areas in one or both eyes (measured
according to the protocol of the Macular Photocoagulation
Study11) showing leakage on fluorescein angiography (FA),
BCVA of 20/40 to 20/320, and central subfield thickness
‡ 250mm measured by optical coherence tomography (OCT),
with no prior history of intravitreal injection of aflibercept or
bevacizumab or ranibizumab. Prior treatment with the fol-
lowing therapies in the study eye was only excluded if
treatment fell within the noted time: laser photocoagulation
or photodynamic therapy or intravitreal triamcinolone
within 12 weeks, intravitreal injection of pegaptanib within 8
weeks, and periocular corticosteroids in the study eye within
6 months of enrollment (See Supplementary Table S1; Sup-
plementary Data are available online at www.liebertpub
.com/jop, for a complete eligibility criteria listing).
Schedule of visits, interventions, and assessments
Patients were evaluated at screening, day 1 (baseline), day 3,
and weeks 1, 2, 4, 6, 8, and 12. Patients were randomly as-
signed to receive the intravitreal injection of either 0.15mg or
4mg aflibercept in a 1:1 ratio. The initial intravitreal injection of
0.15mg or 4mg aflibercept was given at the day 1 baseline
visit; the technique for injection is described below. At week 8,
patients had the option of remaining in the masked phase
through day 85 or entering a 1-year open-label extension phase,
during which patients were evaluated for retreatment based on
the following criteria: (1) an increase in central retinal thickness
of ‡100mm as measured by OCT, (2) a loss of ‡5 Early
Treatment Diabetic Retinopathy Study (ETDRS) letters in con-
junction with recurrent fluid as indicated by OCT, (3) persistent
fluid as indicated by OCT, (4) new onset classic neovascular-
ization, (5) new or persistent leakage on FA, or (6) newmacular
hemorrhage. Safety and efficacy for the masked phase of this
study were evaluated at week 8 and are reported herein.
Intravitreal administration of aflibercept
Intravitreal injections of aflibercept were performed ac-
cording to a prespecified protocol. A sterile lid speculum
was inserted, topical anesthesia was applied, and the con-
junctiva was irrigated with 5% povidone iodine. After ad-
ditional local anesthesia, a 30-gauge needle was inserted
through the pars plana, and the assigned dose of aflibercept
was injected into the vitreous cavity. Funduscopic exami-
nation was then performed to confirm retinal perfusion, and
patients were observed for 1 h or until intraocular pressure
was £ 21mm Hg.
Study assessments
Patients were closely monitored for safety and tolerability
using the following assessments and procedures: BCVA, slit-
lamp biomicroscopy, indirect ophthalmoscopy, tonometry,
AE reporting, vital signs, physical examinations, serum
electrolytes, creatinine, quantitative protein determination in
24-h urine specimens, and measurement of serum neutraliz-
ing antibodies directed against aflibercept. Stereoscopic color
fundus photographs and FA were performed at baseline and
week 6 and OCT was performed at each study visit. OCT was
performed using StratusOCTÒ (Carl Zeiss Meditec, Dublin,
CA) to obtain 6-mm fast macular thickness maps and 6·6-mm
crosshair scans. All images were evaluated by masked
graders at the Digital OCT Reading Center (DOCTR, Cle-
veland, OH). Foveal thickness, defined as the mean height of
the neurosensory retina in a central 1-mm-diameter area, and
total macular volume were automatically computed by the
StratusOCTÒ software version 4. Central retinal/lesion thick-
ness (CR/LT) was manually computed by masked graders.
CR/LT was defined as the distance between the inner limiting
membrane and the inner border of the retinal pigment epi-
thelium/choriocapillaris complex, including any subretinal
fluid and thickness of any observable choroidal neovascular
membrane or scar tissue in the central 1mm of the posterior
pole scan. A posterior pole scan was obtained, consisting of a
high-resolution 7-mm scan from a single scan line from the
meridian of the optic disc margin, declined at a 5-degree angle
through the presumed foveal center. The placement of the scan
line was based on anatomic landmarks as visualized by a
trained, certified operator to offer better registration. FA was
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performed in customary fashion. The Digital Angiographic
Reading Center (DARC, New York, NY) provided a modified
image acquisition protocol and monitored compliance by site
visits. Digital angiogram images were evaluated by masked
graders at DARC.
Data analysis
The primary objective of this phase 1 study was to com-
pare the safety, tolerability, and bioactivity of 0.15mg versus
4mg intravitreal injections of aflibercept. The primary effi-
cacy outcome was the change from baseline to week 8 in
CR/LT. The primary analysis consisted of a paired t-test of
the significance of change from baseline to week 8 by pooling
observations from the 2-dose groups combined. Conditional
on statistical significance of the 1-sample analysis of the
pooled group, an analysis of covariance (ANCOVA) was
conducted to compare the 2-dose groups. The ANCOVA
model was a main-effects model, including baseline CR/LT
as a covariate and treatment as a factor. Secondary outcomes
were the change from baseline to week 8 in BCVA, the
change from baseline to week 6 in CNV lesion size and area
of leakage, and the proportion of patients requiring repeat
injection at 8 weeks. The between-group difference in pro-
portion of patients gaining ‡ 10 letters in BCVA was ana-
lyzed using the Fisher’s exact test. Missing values were
imputed using the last observation carried forward method.
Results
Patient disposition and demographics
Overall, 28 patients were enrolled and 14 each were ran-
domized to receive either 0.15mg or 4mg intravitreal afli-
bercept; all 28 patients were treated as randomized. The
baseline characteristics of the 28 patients included in the
study are listed in Table 1. Fifteen were male, 27 were
Caucasian, and the mean age for all patients combined was
76.3 years. Although the majority of the patients had re-
ceived prior treatment(s) for neovascular AMD, an effort was
made to determine the presence of classic and/or occult
CNV within lesions; history of prior treatments and lesion
types by group are also given in Table 1.
Safety
There were no ocular serious adverse events (SAEs) and
no significant intraocular inflammation in any study eye.
Common ocular AEs are given in Table 2. Conjunctival
hemorrhage, change in refractive state, and reduced visual
acuity were the most common AEs, and rates were similar
between the 2-dose groups.
CR/LT on OCT
Due to the presence of significant artifacts when using
the automated fast macular thickness OCT scans, which
rendered many scans unreadable, a manual measurement
was utilized: (CR/LT), the combined thickness of CNV,
subretinal fluid, and overlying retina in the center of the
macula. Measurements were performed by masked graders
(as described in Materials, Subjects, and Methods section).
The mean change from baseline in CR/LT for the pooled
groups at weeks 4, 6 and 8 was - 128.5 mm (P < 0.0001),
- 79.7 mm (P = 0.0018), and - 97.1 mm (P = 0.0006), respec-
tively. This decrease represented a mean 18.3% reduction in
CR/LT 8 weeks following a single intravitreal injection of
aflibercept.
The mean absolute and percentage decrease in CR/LT of
the study eye from baseline was consistently greater in the
4-mg group than in the 0.15-mg group. The mean percent-
age decrease in CR/LT for the 4-mg and 0.15-mg groups
was, respectively, 34.2% versus 13.3% at week 4, 23.8%
Table 1. Demographics and Baseline Characteristics of the Study Population
0.15mg VEGF Trap (n = 14) 4.0mg VEGF Trap (n = 14)
Mean – SD Median Range Mean – SD Median Range
Age 75.6 – 7.76 76 55–87 76.9 – 6.85 78.5 66–89
Gender (M:F) 8:6 7:7
Study Eye (OD:OS) 6:8 6:8
BCVAa 49.7 – 15.48 46.5 27–75 51.8 – 13.61 54.5 22–73
Snellen Equivalent 20/100 20/125+ 1 20/320+ 2–20/32 20/100 + 1 20/80–1 20/400 + 2–20/32–2
Central Retinal/Lesion
Thickness (CR/LT)
493.9– 170.69 475.8 212–862.5 506.0– 156.02 474 282–873
# of Prior Treatments
in Study Eye (PDT –
steroids, pegaptanib,
bevacizumab)






Minimally Classic 2 3
Occult 11 6
aETDRS letters read as measured by EVA (electronic visual acuity).
BCVA, best corrected visual acuity; PDT, photodynamic therapy; CNV, choroidal neovascularization; FA, fluorescein angiography.
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versus 5.9% at week 6, and 25.2% versus 11.3% at week 8
(Fig. 1A). The percent difference between groups was sta-
tistically significant (by ANCOVA) at week 4 (P = 0.0065)
and week 6 (P = 0.0380), but not at week 8 (P = 0.150)
(Fig. 1A).
Best corrected visual acuity
The mean change from baseline in BCVA for the pooled
groups at weeks 4, 6, and 8 was 3.6 letters (P= 0.0438), 4.8
letters (P = 0.0237), and 2.8 letters (P = 0.1632), respectively.
Table 2. Adverse Events Occurring at a Frequency of > 5% of the Overall Group [n, (%)]
All (n = 28) 0.15-mg Group (n = 14) 4-mg Group (n = 14)
Conjunctival hemorrhage 20 (71.4) 10 (71.4) 10 (71.4)
Refraction disorder 9 (32.1) 4 (28.6) 5 (35.7)
Reduced visual acuity 4 (14.3) 1 (7.1) 3 (21.4)
Anterior chamber cell 2 (7.1) 1 (7.1) 1 (7.1)
Cataract 2 (7.1) 1 (7.1) 1 (7.1)
Increased intraocular pressure 2 (7.1) 1 (7.1) 1 (7.1)
Ocular hyperemia 2 (7.1) 1 (7.1) 1 (7.1)
Vitritis 2 (7.1) 1 (7.1) 1 (7.1)
FIG. 1. (A) Mean percent-
age change from baseline
in combined lesion and fo-
veal thickness between the
0.15-mg and 4-mg doses. The
p-values were calculated for
the difference between the 2
doses and designated as (*) at
week 6 (P = 0.038) and ({) at
week 8 (P = 0.150). (B) Mean
change frombaseline in ETDRS
visual acuity score between the
0.15-mg and 4-mg doses. The
p-values were calculated for
the difference between the 2
doses and designated as (*) at
week 6 (P=0.030) and ({) at
week 8 (P=0.383). ETDRS=
Early Treatment Diabetic
Retinopathy Study. The arrow
(Y) indicates opportunity for
retreatment with vascular
endothelial growth factor
(VEGF) Trap-Eye at week 8 for
patients in both the 0.15-mg
and 4-mg groups.
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At week 8, 20 of 28 patients (71%) had a gain in visual acuity
of 0 or more letters, and 8 patients (29%) had a loss. Six of the
8 patients (75%) who had a decrease in visual acuity were in
the 0.15-mg group.
Beginning at week 4, visual acuity in the 4-mg group was
consistently better than in the 0.15-mg group. Nine of 14
patients (64%) in the 0.15-mg group and 11 of 14 patients
(79%) in the 4-mg group showed stable or improved BCVA
at 8 weeks. The mean improvement in BCVA between
baseline and week 6 was 0.7 letters in the 0.15-mg group and
8.9 letters in the 4-mg group (P = 0.0306). Six of 14 patients
(43%) in the 4-mg dose group had a gain of 10 or more letters
compared to only 1 of 14 (7%) in the 0.15-mg group
(P = 0.0768). At week 8, the difference between the groups
was less pronounced, although the 4-mg group had a better
visual acuity gain (4.5 letters in the 4-mg group and 1.1 let-
ters in the 0.15-mg group, P = 0.3831) (Fig. 1B).
Retreatment at week 8
Based on the criteria defined in the Materials, Subjects,
and Methods section, patients were evaluated by the In-
vestigator at week 8 for a possible second intravitreal injec-
tion of aflibercept. Among the 14 patients injected with 4mg
of intravitreal aflibercept at baseline, 4 patients (29%) were
redosed at week 8. On the other hand, among the 14 patients
treated with 0.15mg of intravitreal aflibercept at baseline, 10
patients (71%) were redosed at this visit (P = 0.0570; Fig. 1).
Persistent fluid was the most common reason for retreatment
in both the 4-mg and 0.15-mg groups.
Representative Selected Cases
Stereoscopic color fundus photography and FA were
performed at baseline and week 6, and OCT was performed
at each study visit for all 28 patients in the study. FA and
OCT images were then sent to DARC and DOCTR for formal
analyses, respectively. Two patients were selected randomly
from each of the 2-dose groups and are discussed in details
to illustrate the bioactivity of intravitreal aflibercept.
Patients 1 and 2 were selected from the 0.15-mg group.
Patient 1 was a 72-year-old man who had CNV in the left
eye, which was treated previously with pegaptanib. Baseline
BCVA was 20/32. Occult CNV with a fibrovascular pigment
epithelial detachment was seen on color photographs and FA.
OCT revealed a corresponding retinal pigment epithelial
(RPE) detachment with subretinal fluid. At week 6 BCVA
was 20/40, and there was persistent CNV leakage and ele-
vation of the RPE on OCT. However, there was a small de-
crease in the amount of subretinal fluid seen on OCT (Fig. 2).
FIG. 2. Color photography,
fluorescein angiography (FA),
and optical coherence tomog-
raphy (OCT) for 2 randomly
selected patients who were
randomized to receive the
0.15-mg dose of VEGF Trap-
Eye: patients 1 and 2. In
patient 1, there was occult
choroidal neovascularization
(CNV) with fibrovascular pig-
ment epithelial detachment
seen on color photographs and
FA, and OCT revealed corre-
sponding retinal pigment epi-
thelial (RPE) detachment with
subretinal fluid. At week 6,
there was persistent CNV
leakage and elevation of the
RPE on OCT. However, there
was a small decrease in the
amount of subretinal fluid
seen on OCT. In patient 2,
color fundus photography and
FA revealed leakage from
subfoveal CNV with cystoid
retinal edema on OCT at the
baseline visit. At week 6, there
was persistent CNV leakage
and an increase in the cystoid
retinal edema seen on OCT.
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Patient 2 was a 78-year-old man who had CNV in the left
eye, which was treated previously with both ranibizumab
and pegaptanib. Baseline BCVA was 20/200. At the baseline
visit, color fundus photography and FA revealed leakage
from subfoveal CNV, with cystoid retinal edema apparent
on OCT. At week 6, BCVA was 20/160. At this visit, there
was persistent CNV leakage and an increase in the cystoid
retinal edema seen on OCT (Fig. 2).
Patients 3 and 4 were selected from the 4-mg group of
intravitreal aflibercept. Patient 3 was an 81-year-old man
who had CNV in the left eye, which was treated previously
with verteporfin photodynamic therapy. Baseline BCVA was
20/400. At the baseline visit, color fundus photography and
FA revealed leakage from subfoveal occult CNV, with cy-
stoid retinal edema and a lamellar hole apparent on OCT. At
week 6, BCVA was 20/160. At this visit, there was no CNV
leakage with complete resolution of the cystoid retinal
edema seen on OCT (Fig. 3).
Patient 4 was an 86-year-old woman who had CNV in the
left eye, which was treatment naive. Baseline BCVA was 20/
80. There was predominantly classic CNV seen on color
photograph and FA at baseline. The corresponding OCT
showed subretinal fluid and intraretinal edema. At week 6,
BCVA was 20/100. At this visit, there was a marked re-
duction in CNV leakage and a significant decrease in sub-
retinal fluid and intraretinal edema (Fig. 3).
Discussion
A previous phase 1 study has demonstrated that an in-
travitreal injection of up to 4mg aflibercept in patients with
AMD was well tolerated with no ocular inflammation.10 The
current phase 1 study has confirmed that eyes treated with
4mg intravitreal aflibercept showed no evidence of inflam-
mation and were indistinguishable from eyes injected with
0.15mg of intravitreal aflibercept with regard to safety and
tolerability. The safety and tolerability profiles of both doses
were identical during the 8-week study, with AEs generally
being mild-to-moderate and self-limited. The most common
AE was conjunctival hemorrhage, which is common to all
drugs administered by an intravitreal injection. No drug-
related SAEs were observed.
Neovascular AMD is a significant cause of vision loss. In
recent years, VEGF inhibition has become an important
strategy in managing the disease. There remains an unmet
need in neovascular AMD therapeutics, both in terms of
FIG. 3. Color photography,
FA, and OCT for 2 randomly
selected patients who were
randomized to receive the
4-mg dose of VEGF Trap-Eye:
patients 3 and 4. In patient 3,
color fundus photography
and FA revealed leakage
from subfoveal occult CNV
with cystoid retinal edema
and a lamellar hole on OCT
at the baseline visit. At week
6, there was no CNV leakage
on FA, and resolution of the
cystoid retinal edema on
OCT. In patient 4, there was
predominantly classic CNV
seen on color photograph and
FA at baseline. The corre-
sponding OCT showed sub-
retinal fluid and intraretinal
edema. At week 6, there was
a marked reduction in CNV
leakage and a significant de-
crease in subretinal fluid and
intraretinal edema.
586 NGUYEN ET AL.
enhancing drug activity and in optimizing drug delivery.
Aflibercept has a high-binding affinity for VEGF and also
binds PlGF with high affinity, characteristics that may dis-
tinguish intravitreal aflibercept from other anti-VEGF treat-
ments currently used to treat neovascular AMD.7 Currently,
all anti-VEGF drugs used to treat neovascular AMD are
delivered via the intravitreal injection. Ranibizumab is indi-
cated for monthly injections. However, the intravitreal in-
jection is not without risks. An improvement to the current
therapeutic options would be to increase the duration of
drug activity, so that intravitreal injections can be ad-
ministered less frequently. In the current study, a single
intravitreal injection of aflibercept provided significant
thinning of the thickened retina and lesion at 8 weeks.
The patients enrolled in this primarily safety study had
advanced AMD with active neovascularization, intraretinal
and/or subretinal fluid, and submacular fibrosis. Despite the
advanced stage of disease, CR/LT improved by statistically
significant amounts ranging from approximately 80–130mm
over 8 weeks post-treatment in the pooled group and trended
toward greater improvement in the 4-mg group compared
with the 0.15-mg group. Similarly, BCVA demonstrated im-
provement after treatment in the pooled group, with statisti-
cally significant visual gains at 4 and 6 weeks post-treatment;
again, a trend was observed toward greater visual gains in the
higher dose group. At the 8-week visit, more than twice as
many patients in the 0.15-mg group needed redosing com-
pared with patients in the 4-mg group, suggesting that there
was a dose–response and that the higher dose of intravitreal
aflibercept appeared to have a stronger bioactivity in control-
ling CNV in neovascular AMD. The fact that fewer patients in
the higher dose group met retreatment criteria may also sug-
gest that higher doses of intravitreal aflibercept may provide
longer duration of activity in patients with neovascular AMD.
Interestingly, during the first 10–15 days after intravitreal
administration of aflibercept, the median decrease in CR/LT
was similar between the 2-dose groups, 0.15 and 4mg.
However, by week 4, there was a clear separation between
the 2-dose groups, with the higher dose clearly demonstrat-
ing superior efficacy over the lower dose. It is possible that
initially, the presence of intravitreal aflibercept at both doses
was sufficient to bind the VEGF molecules present in the eye,
leading to decreased thickness. However, as VEGF continues
to be produced over time, a higher concentration of afli-
bercept may be more capable of continuing to provide suf-
ficient inhibition, resulting in more advantageous outcomes.
The changes in visual acuity over time were less simple to
explain. Although beginning at week 4, there was a clear
demonstration (Fig. 1B) that the 4-mg dose led to a more
significant improvement in visual acuity than the 0.15-mg
dose at weeks 6 and 8, such changes were not obvious during
the first 15 days. Within the first 2 weeks, the 0.15-mg dose
produced a better visual gain than the 4-mg dose, although
both doses produced similar reduction in retinal thickness.
The reasons for such observation are not clear, and may be
due to the variations seen with a small study population
and/or the lower baseline visual acuity in the 0.15-mg group,
which may have allowed for initial improvements in visual
acuity following intravitreal aflibercept administration.
The difference in bioactivity between the 0.15-mg and the
4-mg doses is further apparent when considering the 4 ran-
domly selected representative patients. The 2 patients who
were treated with the 0.15-mg dose did not show much
improvement based on FA and OCT. The CNV remained
with active leakage, and OCT showed very little change in
the amount of intraretinal and subretinal fluid. On the other
hand, the 2 patients who were treated with the higher 4-mg
dose clearly demonstrated improvement in the activities of
the CNV, with complete resolution of leakage on FA and
fluid on OCT. Such results help to provide uncontroversial
support for a dose–response effect of intravitreal aflibercept
in neovascular AMD. Equally important is the lack of any
increase in AEs associated with the higher dose, suggesting
that the higher dose of intravitreal aflibercept may have in-
creased bioactivity, but did not carry additional risks of
deleterious effects during the 8-week study.
In summary, the current study suggests that intravitreal
therapy with 4mg of aflibercept is well tolerated and has a
substantial biological activity that may last up to 8 weeks in
patients with CNV secondary to AMD. The study also pro-
vides additional data to support a dose-dependent bioac-
tivity of intravitreal aflibercept. It is clear from this short-
term study that the 4-mg dose had an equivalent safety
profile with increased bioactivity as compared to the 0.15-mg
dose for 8 weeks. Additional studies will help to elucidate
optimal dosing and administration frequency with in-
travitreal aflibercept in patients with neovascular AMD.
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